The Enzap trial enrolled patients with metastatic castration-resistant prostate cancer who had not previously received docetaxel or androgen receptor pathway inhibitors and displayed PSMA-positive PET/CT scans with [68Ga]Ga-PSMA-11. This evidence concerns the gene FOLH1 and Familial prostate cancer.